Can Trump Plan Serve as Model for What Ails Europe?

Now Donald Trump has at last made his pitch to tackle the challenge of paying for drugs in the US, speculation is rife about what the impact could be around the world and healthcare payers in Europe are combing through his 44-page blueprint to see if any of his ideas might be worth a try locally Powered by WPeMatico Continue reading Can Trump Plan Serve as Model for What Ails Europe?

Digital Health: Regulatory, Compliance, and Legal Challenges

At this month’s AMPLEXOR Life Sciences Be The Expert conference in Dubrovnik, Croatia, Ilyssa Levins, president and founder of the Center for Communication Compliance , talked about some of the regulatory, compliance and legal challenges posed by the digital health revolutio Powered by WPeMatico Continue reading Digital Health: Regulatory, Compliance, and Legal Challenges

Improving Regulatory Resource Management through Systematic Measurement

As submissions complexity intensifies, life sciences firms are finding that the key to better resource management is better measurement, writes Adrian Leibert. Regulatory demands in the life sciences world are not only increasing in volume and complexity; submissions workloads are also Powered by WPeMatico Continue reading Improving Regulatory Resource Management through Systematic Measurement

Pharma’s Image Fix: Lessons from the Field

The importance of an “adaptive” command style in pharma today Lieutenant General (Ret) Rick Lynch, US Army and Bob Jansen, CEO of Zensights, Pharm Exec Editorial Advisory Board member, and former president and general manager of Source Healthcare Analytics, a Symphony Powered by WPeMatico Continue reading Pharma’s Image Fix: Lessons from the Field

Accentuate the Positive: Tackling Pharma s Reputation Problem

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to stakeholders Merck s Head Defends Drug Prices, ran The New York Times headline. The Times was reporting on the Merck & Co. president s Powered by WPeMatico Continue reading Accentuate the Positive: Tackling Pharma s Reputation Problem

The Chinese Pharmaceutical Industry: Winners and Losers 2017

Jin Zhang reviews the current fortunes of the Chinese pharmaceutical companies. Recently, East Money Information published their latest Chinese Top 500 company list of 2017. Among them, 42 pharmaceutical companies were listed and arranged into three distinctive tiers. So, who are t Powered by WPeMatico Continue reading The Chinese Pharmaceutical Industry: Winners and Losers 2017

The Innovation Distinction: Biopharma’s Reputational Pass

Fair or not, biotech has managed to elude perception crosshairs While traditional pharmaceutical companies are taking a reputational hit, biotech organizations, for the most part, are getting a public-perception pass for now. Whether or not it s fair, or accurate, in ge Powered by WPeMatico Continue reading The Innovation Distinction: Biopharma’s Reputational Pass

Health Policy Problem Solver: Fumie Griego

Turning Ideological Challenges into Practical Solutions The Geneva, Switzerland-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. It has consultative status w Powered by WPeMatico Continue reading Health Policy Problem Solver: Fumie Griego

Congress Meets Deadline for Reauthorizing FDA User Fees

Before leaving Washington for a delayed August recess, the Senate voted 94-1 to approve legislation reauthorizing user fees and a series of program changes critical to maintaining a smoothly functioning FDA medical product review and approval process. The fees included in the FDA Reauthorization Powered by WPeMatico Continue reading Congress Meets Deadline for Reauthorizing FDA User Fees